ArticleJournal of pediatric gastroenterology and nutrition2026
Healthcare resource utilization and cost in pediatric celiac disease: A case-control study using German insurance data.
Article in Journal of pediatric gastroenterology and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Healthcare resource utilization and cost in pediatric celiac disease: A case-control study using German insurance data.Journal of pediatric gastroenterology and nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesCeliac disease (CeD) is a life-long systemic immune-mediated disorder. Data on burden and cost of CeD in children are scarce. We assessed healthcare resource utilization (HCRU) and cost of healthcare services of newly diagnosed children in Germany.
methodsThis retrospective case-control study covered a period from 2014 to 2021, using German Statutory Health Insurance claims data from the "Institute for Applied Health Research Berlin" (InGef). The HCRU (hospitalizations, outpatient contacts, outpatient drug prescriptions) and cost of CeD patients aged <6 (group 1) and 6-11 years (group 2) between 2017 and 2019 were compared with matched non-CeD individuals (1:5 matching by age, sex, Charlson Comorbidity Index, and region) during the time of diagnosis and 2 years thereafter. Case definition required ≥1 diagnosis of CeD (ICD-10-GM K90.0) as inpatient or ≥2 recorded diagnoses as outpatient plus ≥1 CeD-related serological test, and no recorded CeD diagnoses during the 3-year preobservation period.
resultsWe identified 410 CeD cases resulting in incidence rates of 32.5 and 34.1 per 100,000 individuals in groups 1 and 2, respectively. During time of diagnosis and 2 years thereafter, CeD patients had increased HCRU (median) compared to their controls (two more hospitalizations, almost three-times more outpatient contacts, and 3-4 more prescriptions), resulting in higher total costs (median difference €1677 and €1343 in group 1 and 2, respectively) (all p < 0.001).
conclusionsThese findings underscore the substantial burden of CeD on patients and healthcare systems, highlighting the need for targeted interventions and effective management strategies to mitigate this impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.